Featured News See All March 11, 2026 REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 March 5, 2026 REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights March 4, 2026 REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Year All20262025202420232022202120202019201820172016201520142013201220112009 Jan 11, 2026 REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
Jan 11, 2026 REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
